 The study aimed to standardize laboratory monitoring protocols for adverse effects in patients with acne treated with systemic isotritinoin by using the National Cancer Institute common terminology criteria for adverse events version 3.0 grading system and reviewing medical charts of 704 patients. The results showed that the most common laboratory abnormalities were related to liver function, lipid levels, and CBC, which were reversible and did not require discontinuation of treatment. Therefore, frequent biochemical monitoring is not recommended for patients with acne treated with systemic isotritinoin. This article was authored by EyesOctam, YLDZ Haran, SRR, and others.